10-K/A: Dalrada Financial Reports Steep Losses and Revenue Decline Amidst Going Concern Doubts and Extensive Litigation

Dalrada Financial Corporation reported a significant increase in net loss and a substantial decline in revenues across all its business segments for the fiscal year ended June 30, 2024, raising substantial doubt about its ability to continue as a going concern.

Summary

• Dalrada Financial Corporation reported a net loss of $29,185,898 for the fiscal year ended June 30, 2024, a significant increase from the $20,627,721 net loss in the prior year.
• Total revenues decreased by 33.3% to $19,842,419 in FY2024 from $29,738,969 in FY2023.
• Gross profit plummeted by 89.2% to $984,032 in FY2024 from $9,059,919 in FY2023.
• The company's working capital deficit worsened to $7,085,306 as of June 30, 2024, compared to a deficit of $202,420 as of June 30, 2023.
• Cash used in operating activities increased to $7,873,760 in FY2024 from $4,612,798 in FY2023.
• Genefic segment revenues decreased by 16.0% to $13,217,899, primarily due to the closure of COVID-19 testing laboratories (Pala and Empower Diagnostics).
• Dalrada Climate Technology revenues decreased by 60.4% to $2,804,236, largely due to nearing completion of the Averett University project and delays in commercializing the DCT-1 heat pump.
• Dalrada Precision Manufacturing revenues decreased by 49.8% to $2,447,148, attributed to the loss of a primary customer in precision parts manufacturing and ramping down Ignite operations.
• Dalrada Technologies revenues decreased by 33.0% to $1,373,136, as several contracts ended their terms.
• The company continues to rely on equity and debt investors to finance its losses, with significant related party debt conversions and new loan agreements.
• Material weaknesses in internal control over financial reporting were identified, specifically regarding inadequate schedules for roll forwards, revenue recognition, and allowance estimates, and a lack of a comprehensive financial reporting policies manual.

Sentiment

Score: 2

Explanation: The company reported a significantly increased net loss and negative working capital, raising substantial doubt about its ability to continue as a going concern. Revenues declined across all segments, and the company continues to rely heavily on debt and equity financing, including from related parties. Multiple ongoing legal proceedings and identified material weaknesses in internal controls further contribute to a highly negative outlook.

Positives

• Genefic Specialty Pharmacy obtained additional accreditations (NABP Healthcare Merchant, URAC Specialty Pharmacy, and Mail Service Pharmacy) which allowed for a ramp-up of sales and the ability to fill specialty medications, including new hemophilia contracts.
• Dalrada Career Institute (DCI) increased revenue by 22.6% due to obtaining Licensed Vocational Nursing (LVN) accreditation and a rising number of students in its certification programs.
• The U.S. Government selected Dalrada Climate Technology's DCT One Series high-performance, low-carbon heat pump for real-world testing in a prestigious clean energy program, with expected positive results to accelerate market adoption.
• The company has undertaken plans and initiatives to cut costs across all segments and focus sales teams on products and services to generate immediate sales.
• Several legal proceedings, including the joint venture dispute with Vivera Pharmaceuticals and the non-compete lawsuits with Kroger Specialty Pharmacy, were settled and dismissed in early 2025.

Negatives

• The company's net loss significantly increased to $29.19 million in FY2024, up from $20.63 million in FY2023.
• Total revenues decreased substantially by 33.3% year-over-year, indicating a broad decline across business segments.
• Gross profit experienced a drastic 89.2% reduction, highlighting increased cost of revenues relative to sales.
• The working capital deficit worsened considerably to $7.08 million, indicating a severe liquidity challenge.
• Cash used in operating activities increased, demonstrating a higher burn rate from core business operations.
• Dalrada Climate Technology experienced delays in commercializing its proprietary DCT-1 heat pump and ramping up its residential heat pump platform, while facing high operating costs.
• Dalrada Precision Manufacturing lost a significant primary customer, leading to a material loss in revenue and cash flow.
• The Corporate segment continued to generate significant expenses, contributing to overall losses.
• The company's independent registered public accounting firm raised substantial doubt about its ability to continue as a going concern.
• Several related party notes payable are in default, although the company has not received formal notices or demands for payment.

Risks

• The company's recurring losses from operations and negative working capital raise substantial doubt about its ability to continue as a going concern.
• Inability to effectively implement cost savings, grow profitable subsidiaries, or secure additional financing could prevent the company from meeting financial obligations.
• Future equity or convertible securities issuances could result in substantial dilution to existing stockholders.
• A decline in the market price of common stock could make it more difficult to raise future equity or equity-related securities.
• The company faces ongoing cybersecurity threats and breach attempts, which, despite not being material to date, could have a material adverse effect if successful.
• Ongoing legal proceedings, including breach of contract claims, tortious interference, fraud, and labor law violations, pose financial and operational risks.
• Reliance on related party funding and transactions introduces potential conflicts of interest and financial dependencies.
• The company has identified material weaknesses in its internal control over financial reporting, which could lead to material misstatements in financial statements.

Future Outlook

The company anticipates incurring additional expenses on research and development over the next 12 months. Management plans to achieve cost savings, focus on growing the most profitable subsidiaries, reduce investments in areas not expected to have long-term benefits, and pursue synergistic opportunities. They also plan to finish percentage-of-completion projects and pursue partnerships to expedite the commercialization of the DCT-1 heat pump. However, the company cannot be certain that these plans will be effectively implemented within one year, and it is unlikely to generate sufficient cash flows to meet financial obligations without raising additional capital.

Management Comments

• "The Company continues to focus on growing the subsidiaries anticipated to be most profitable while reducing investments in areas that are not expected to have long-term benefits."
• "The Company will continue to pursue synergistic opportunities to enhance its business portfolio."
• "Our plans include finishing the percentage of completion projects and pursuing partnerships to help expedite the commercialization of the DCT-1 heat pump."
• "We cannot be certain that our plans and initiatives would be effectively implemented within one year after the filing date of this report."
• "Without giving effect to the prospect of raising additional capital, increasing product revenue in the near future or executing other mitigating plans, many of which are beyond our control, it is unlikely that we will be able to generate sufficient cash flows to meet our required financial obligations, including our debt service and other obligations due to third parties."

Industry Context

Dalrada operates across highly diverse sectors including healthcare, climate technology, precision manufacturing, and information technology. The decline in its Genefic segment's revenue, particularly from COVID-19 testing, reflects the winding down of pandemic-related demand. The challenges in Dalrada Climate Technology, including delays in commercializing heat pumps, indicate difficulties in a competitive and evolving clean energy market. The loss of a major customer in precision manufacturing highlights vulnerability to customer concentration. The overall revenue decline and significant losses suggest that Dalrada is struggling to gain traction and profitability across its varied ventures, potentially lagging behind more focused and established players in each respective industry.

Comparison to Industry Standards

• The document does not provide specific industry benchmarks or comparable companies for a detailed assessment.
• Given the substantial increase in net loss and significant revenue declines across all operating segments, Dalrada's financial performance is considerably worse than typical industry standards for healthy, growing companies in the healthcare, climate technology, manufacturing, and IT sectors.
• The company's negative working capital and reliance on continuous debt and equity financing, including from related parties, indicate a financial position that is far below industry norms for sustainable operations.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit filed by Genefic Products (Dalrada Health) against Vivera Pharmaceuticals, Inc. for $2,104,509 in misappropriated funds was dismissed on January 13, 2025.
• Lawsuits filed by Kroger Specialty Pharmacy LLC against Genefic Specialty Pharmacy and two employees regarding non-compete clauses were settled and dismissed on March 19, 2025.
• Asset Group, Inc. filed a breach of contract suit against Dalrada Health Products (DHP) for $3,240,000; DHP filed a cross-complaint for tortious interference, with a jury trial scheduled for September 19, 2025.
• MDIQ filed a breach of contract suit against Dalrada Financial Corporation (DFCO) for unpaid invoices; DFCO is counter-suing for approximately $2,000,000 in unpaid claims due to MDIQ's alleged failure to perform.
• DFCO filed a lawsuit against DePrey Company and Simon Gray for breach of contract and intentional interference related to stolen purchase orders.
• DFCO filed a lawsuit against Stuart Cox (seller of Likido company) alleging fraud, breach of contract, and unjust enrichment for failure to disclose financial liabilities; settlement negotiations are ongoing.
• DFCO filed a lawsuit against former UK subsidiary employees and directors (William Bonar, Samantha and Ian MacKenzie, Jillian Hughes, Marion Bonar) alleging fraud, tortious interference, and misappropriation of trade secrets.
• FFF Enterprises filed a lawsuit against Genefic, Inc. and DFCO for alleged breach of a service agreement, demanding $564,743.48; Genefic/DFCO filed a motion to dismiss DFCO as a defendant, and settlement negotiations are ongoing.
• A former employee filed a complaint alleging numerous labor law violations after being laid off, with a jury trial scheduled for October 10, 2025.
• Lamie RB Investments, LLC filed a suit for breach of a lease contract with Genefic, Inc., seeking damages equal to the lease term; Genefic, Inc. filed a motion to dismiss for failure to mitigate damages.

Related Party Transactions

• The company received cash funding or expenses paid on its behalf from related parties totaling $2,923,418 in FY2024 and $5,439,249 in FY2023, primarily for operational expenditure and payroll, often formalized as promissory notes.
• As of June 30, 2024, $136,976 was included in accounts payable and accrued liabilities for related party expenses.
• In FY2023, the company incurred $5,312,020 in expenses for services provided by related parties, including management, payroll processing, rent, and chartered flight services.
• Bothof Brothers subsidiary recognized revenue of $1,697,485 in FY2024 and $2,134,470 in FY2023 from corporations owned and/or operated by a related party.
• Dalrada Energy Services recognized monthly interest income and royalty revenue of $5,207 in FY2024 and $45,968 in FY2023 from related parties.
• The company incurred $1,669,788 in services performed by non-employee board members in FY2023.
• Significant amounts of related party debt principal and interest were converted into Series I Convertible Preferred Stock in FY2024 ($13,318,943, $4,440,000, and $3,924,499).
• The CEO's employment agreement includes a base salary of $393,000 per annum (deferred and accrued), annual increases, and eligibility for a quarterly bonus based on net profit, along with a 10% ownership position post-reverse split.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing equity and convertible preferred stock issuances, particularly from related party debt conversions. The substantial net losses and going concern warning indicate a high risk to investment value. The change in OTC Markets status to 'Expert Market' may reduce liquidity and transparency.
• **Employees**: Experienced layoffs, leading to a labor law violation complaint. Employee compensation and benefits increased in the Genefic segment due to growth, but decreased in Corporate and Precision Manufacturing due to reductions in corporate employees and activity.
• **Customers**: May experience impacts from operational ramp-downs (e.g., Ignite) or delays in product commercialization (e.g., DCT-1 heat pump). The loss of a primary customer in Precision Manufacturing indicates potential service disruption for some clients.
• **Suppliers**: The company's financial instability and reliance on debt financing could pose risks to suppliers regarding timely payments, although accounts payable increased in FY2024.
• **Creditors**: Face elevated risk due to the company's recurring losses, negative working capital, and the 'going concern' doubt. Several related party notes are in default, and the company continues to draw on new loans and revenue purchase agreements.

Next Steps

• Achieve cost savings across all segments.
• Focus sales teams on products and services to generate immediate sales.
• Finish percentage of completion projects.
• Pursue partnerships to help expedite the commercialization of the DCT-1 heat pump.
• Double the class size for Dalrada Career Institute's RN nursing program in 2025.
• Remediate identified material weaknesses in internal control over financial reporting by standardizing reconciliation processes, engaging outside advisors, and enhancing policies and procedures.

Key Dates

Recommendation

Keywords

Dalrada Financial Corporation, DFCO, SEC Filing, 10-K/A, Financial Performance, Net Loss, Revenue Decline, Going Concern, Working Capital Deficit, Healthcare Solutions, Climate Technology, Precision Manufacturing, Information Technology, Specialty Pharmacy, Heat Pumps, Semiconductor Equipment, Digital Engineering, Corporate Governance, Legal Proceedings, Related Party Transactions, Capital Raise, Stock-Based Compensation, Internal Controls